Trade Summary

5 days ago, Savitz Ryan, serving as EVP, CFO, CBO at Dianthus Therapeutics, Inc. /De/ (DNTH), sold 114,367 shares at $83.00 per share, for a total transaction value of $9,492,596.00.

This sale represents a 100.00% decrease in Savitz Ryan's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, March 31, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 1, 2026, 1 day after the trade was made.

Dianthus Therapeutics, Inc. /De/ operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.